Pharsight

Pedmark is owned by Fennec Pharms Inc.

Pedmark contains Sodium Thiosulfate.

Pedmark has a total of 3 drug patents out of which 0 drug patents have expired.

Pedmark was authorised for market use on 20 September, 2022.

Pedmark is available in solution;intravenous dosage forms.

Pedmark can be used as a method of reducing ototoxicity in a human pediatric patient about 5 years of age or under with localized medulloblastoma comprising administering sodium thiosulfate about six hours after administration of cisplatin.

The generics of Pedmark are possible to be released after 01 July, 2039.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US10596190	October, 2021	Trial Instituted	Oregon Health & Science University et al.	Hope Medical Enterprises, Inc.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596190	FENNEC PHARMS INC	Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy	Jan, 2038 (14 years from now)
US11291728	FENNEC PHARMS INC	Anhydrous sodium thiosulfate and formulations thereof	Jul, 2039 (16 years from now)
US11510984	FENNEC PHARMS INC	Anhydrous sodium thiosulfate and formulations thereof	Jul, 2039 (16 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Sep 20, 2025
Orphan Drug Exclusivity (ODE)	Sep 20, 2029

Drugs and Companies using SODIUM THIOSULFATE ingredient

Market Authorisation Date: 20 September, 2022

Treatment: A method of reducing ototoxicity in a human pediatric patient about 5 years of age or under with localized medulloblastoma comprising administering sodium thiosulfate about six hours after administration of cisplatin

Dosage: SOLUTION;INTRAVENOUS